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C OMPARISON OF REC TAL DIAZ E PA M GEL A ND PL ACEB O FOR ACUTE R EPETITIV E SEIZUR ES

A COMPARISON OF RECTAL DIAZEPAM GEL AND PLACEBO FOR ACUTE
REPETITIVE SEIZURES
FRITZ E. DREIFUSS, M.D.,* N. PAUL ROSMAN, M.D., JAMES C. CLOYD, PHARM.D., JOHN M. PELLOCK, M.D.,
RUBEN I. KUZNIECKY, M.D., WARREN D. LO, M.D., FUMISUKE MATSUO, M.D., GREGORY B. SHARP, M.D.,
JOAN A. CONRY, M.D., DONNA C. BERGEN, M.D., AND WALTER E. BELL, PH.D.

ABSTRACT
Background Acute repetitive seizures are readily
recognizable episodes involving increased seizure
frequency. Urgent treatment is often required. Rectal
diazepam gel is a promising therapy.
Methods We conducted a randomized, doubleblind, parallel-group, placebo-controlled study of
home-based treatment for acute repetitive seizures.
Patients were randomly assigned to receive either
rectal diazepam gel, at doses ranging from 0.2 to 0.5
mg per kilogram of body weight on the basis of age,
or placebo. Children received one dose at the onset
of acute repetitive seizures and a second dose four
hours later. Adults received three doses — one dose
at onset, and two more doses 4 and 12 hours after
onset. Treatment was administered by a care giver,
such as a parent, who had received special training.
The number of seizures after the first dose was
counted for 12 hours in children and for 24 hours in
adults.
Results Of 125 study patients (64 assigned to diazepam and 61 to placebo) with a history of acute repetitive seizures, 91 (47 children and 44 adults) were
treated for an exacerbation of seizures during the
study period. Diazepam treatment was superior to
placebo with regard to the outcome variables related
to efficacy: reduced seizure frequency (P<0.001) and
improved global assessment of treatment outcome
by the care giver (frequency and severity of seizures
and drug toxicity) (P<0.001). Post hoc analysis
showed diazepam to be superior to placebo in reducing seizure frequency in both children (P<0.001)
and adults (P=0.02), but only in children was it superior with regard to improvement in global outcome (P<0.001). The time to the first recurrence of
seizures after initial treatment was longer for the patients receiving diazepam (P<0.001). Thirty-five patients reported at least one adverse effect of treatment; somnolence was the most frequent. Respiratory
depression was not reported.
Conclusions Rectal diazepam gel, administered at
home by trained care givers, is an effective and welltolerated treatment for acute repetitive seizures.
(N Engl J Med 1998;338:1869-75.)
©1998, Massachusetts Medical Society.

E

PILEPSY is among the most common neurologic disorders, affecting approximately
two million people in the United States.1
Epileptic-seizure recurrences sometimes follow a distinctive temporal pattern.2,3 Some patients
periodically have repetitive seizures, lasting minutes
or hours, whose pattern is different from their usual
seizure pattern. These exacerbations are termed serial, cluster, or acute repetitive seizures.4,5
Family members are often able to predict the onset of acute repetitive seizures according to the time
of day when the seizures begin, the occurrence of a
particular type of seizure, the severity of the seizure,
and accompanying behavioral changes in the patient. If they are left untreated, acute repetitive seizures can evolve into more serious problems, including status epilepticus.4-6
Benzodiazepines are the treatment of choice for
management of acute seizures.4,7 They are active
against many types of seizure, have a rapid onset of
action, and are safe.7 Oral diazepam and lorazepam,
sublingual lorazepam, rectal solutions of lorazepam
and diazepam, and diazepam suppositories have been
used to treat acute repetitive seizures.8-13 Oral or
sublingual administration is frequently difficult and
hazardous when the patient is actively convulsing,
and absorption of diazepam and lorazepam tablets
and rectal lorazepam solution is slower than that of
rectal diazepam solutions.8,14,15
Rectal diazepam solutions have many characteristics sought in the ideal drug to treat acute repetitive
seizures. Their high lipid solubility permits both
prompt absorption and rapid penetration into the
central nervous system.16 Peak serum plasma concentrations are reached within 5 to 45 minutes, with

From the Department of Neurology, University of Virginia, Charlottesville (F.E.D.); the Division of Pediatric Neurology, New England Medical
Center, Boston (N.P.R.); the College of Pharmacy, University of Minnesota, Minneapolis (J.C.C.); the Department of Neurology, Medical College
of Virginia, Richmond (J.M.P.); the Department of Neurology, University
of Alabama at Birmingham, Birmingham (R.I.K.); the Department of Pediatrics, Children’s Hospital, Columbus, Ohio (W.D.L.); the Department
of Neurology, University of Utah, Salt Lake City (F.M.); the Department
of Neurology, Arkansas Children’s Hospital, Little Rock (G.B.S.); the Department of Neurology, Children’s National Medical Center, Washington,
D.C. (J.A.C.); the Department of Neurological Sciences, Rush–Presbyterian–St. Luke’s Medical Center, Chicago (D.C.B.); and the National Institutes of Health, Bethesda, Md. (W.E.B.). Address reprint requests to Dr.
Rosman at the Division of Pediatric Neurology, NEMC 330, Floating
Hospital for Children, 750 Washington St., Boston, MA 02111.
*Deceased.

Vol ume 338

Numb e r 26

The New England Journal of Medicine
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 21, 2015. For personal use only. No other uses without permission.
Copyright © 1998 Massachusetts Medical Society. All rights reserved.

·

1869

The Ne w E n g l a nd Jo u r n a l o f Me d ic i ne

bioavailability averaging between 80 and 100 percent.8,9,13,16-20 In contrast, diazepam suppositories
have slow, erratic absorption, which limits their use
in the management of acute seizures.13,17,19 Rectal diazepam solutions can be administered easily and
safely by nonmedical personnel, irrespective of the
patient’s ability to cooperate.
Both European and North American clinicians
have used rectal diazepam to treat acute repetitive,
prolonged, and febrile seizures.12,16,21,22 In the United States, rectal diazepam solutions have been prepared from commercial parenteral products.8,23-25
In 1988, Upsher–Smith Laboratories, in collaboration with the University of Minnesota, began developing a rectal diazepam delivery system to treat
acute repetitive seizures. We conducted a clinical trial to assess the safety and efficacy of diazepam rectal
gel for acute repetitive seizures.
METHODS
Patients
The patients were boys and girls 2 to 14 years of age and adults,
defined as 15 to 60 years of age, with a maximal weight of 100
kg, who had had at least four episodes of acute repetitive seizures
during the preceding year and at least one in the preceding three
months. We defined acute repetitive seizures as an episode of
multiple complex partial or generalized (tonic, clonic, tonic–
clonic, atypical absence, or myoclonic) seizures occurring within
a 24-hour period in adults or a 12-hour period in children, with
a pattern distinguishable from the patient’s usual seizure pattern,
and with onset readily recognizable by a care giver, such as a parent. All patients had been on a stable antiepileptic regimen for at
least four weeks before enrollment. Brain computed tomography
or magnetic resonance imaging and laboratory screening had
shown no evidence of a treatable cause of the seizures. Women of
childbearing potential were eligible if they used contraception
and had a negative pregnancy test.
Patients were ineligible if they met any of the following criteria:
plasma phenobarbital concentrations greater than 30 mg per liter
(130 µmol per liter), current treatment with drugs other than anticonvulsants, long-term use of benzodiazepines, use of central
nervous system depressants or drugs interacting with diazepam,
more than one previous treatment with rectal diazepam, nonepileptic seizures within the preceding five years, habitual progression to status epilepticus, clinically significant psychiatric disorder,
lack of a suitable care giver, or use of an investigational drug or
device within the preceding five months. Each patient, parent, or
legal guardian provided written informed consent, and children
gave assent.
Study Design
The study was conducted between October 1991 and January
1995. We used a prospective, randomized, double-blind, placebo-controlled, parallel-group design. A sample size of 144 patients was planned on the basis of estimates of the sample size required for a two-sided test to detect a 50 percent reduction in
seizure frequency with diazepam at a significance level of 0.05
and a power of 0.80.
Each center’s institutional review board approved the protocol
and consent procedures. Oversight included regular review by the
National Institute of Neurological Disorders and Stroke Performance and Safety Monitoring Board. Because of the board’s concern about the safety of the investigational formulation and the
response of the acute repetitive seizures to treatment, it requested
an unblinded interim analysis of efficacy and all safety data for the
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first 36 patients. The board did not disclose the results or change
the study at the time of this analysis. Thereafter, the blinding was
maintained until the trial had been completed and decisions
about the inclusion of patients in the analyses had been made.
Randomization was based on permuted blocks, with stratification
according to center and age group.
Procedures
Using an instructional videotape, study nurses taught care givers how to identify episodes of acute repetitive seizures, give medication, and record respiration, skin color, seizures, adverse
events, and global assessment of treatment outcome in a booklet.
During episodes of acute repetitive seizures, study nurses maintained telephone contact with the care givers to review procedures, monitor patients, and intervene if patients needed additional treatment. The observation period began immediately after
the first dose and continued for 12 hours in children and 24
hours in adults. The lengths of the observation periods were
based on preliminary data showing that most episodes of acute
repetitive seizures ended within these times. The care givers and
patients returned to the clinic 72 hours after treatment to review
the recorded data.
We removed patients from the study before treatment if they
no longer met eligibility criteria or if they withdrew consent. All
data were analyzed, including those on patients who did not
complete the protocol.
Study Treatments
We employed an age-adjusted dosage regimen of diazepam rectal gel (Diastat, Athena Neurosciences, San Francisco), as follows:
0.5 mg per kilogram of body weight for children 2 to 5 years of
age, 0.3 mg per kilogram for children 6 to 11 years of age, and
0.2 mg per kilogram for patients 12 or older. These schedules
were based on the results of clinical trials showing that diazepam
clearance in children declines until about the age of 12 years,
when adult values are reached.8,16,19,26 A second dose was given
four hours after the first, and, for adults, a third dose was given
eight hours after the second, since previous studies indicated that
these schedules should maintain target plasma diazepam concentrations (150 to 300 ng per milliliter).8,19,26 Diazepam rectal gel
(5 mg per milliliter) and identical-looking placebo were supplied
by the manufacturer in 2-ml syringes containing 0.5, 1.0, or 1.5
ml and 5-ml syringes containing 2.0, 2.5, 3.0, 3.5, or 4.0 ml. Diazepam doses ranged from 2.5 to 20 mg, in 2.5-mg increments.
The doses were rounded up to the nearest 2.5 mg.
The medication kits contained two syringes for children and
three syringes for adults, with one dose per syringe. A syringe
with half the regular dose was available to be used if the regular
dose was expelled within five minutes.
Outcome Variables Related to Efficacy
Seizure frequency and global assessment of treatment outcome
by the care giver were the outcome variables related to efficacy.
Seizure frequency was defined as the number of seizures per hour
of observation. Global treatment outcome was a composite evaluation based on the care giver’s assessment of the frequency and
severity of seizures and drug toxicity. The global outcome was
rated as better than, the same as, or worse than the outcome after
previous episodes.
Two efficacy outcome variables were retrospectively defined:
the time to the first recurrence of seizures after the initial treatment, and the number of patients remaining seizure-free during
the first 12 hours after treatment.
Safety Variables
At the return visit, the notes in the care giver’s booklet about
respiratory rate, skin color, and adverse events were reviewed. All
adverse events were categorized according to the preferred terms
of the Food and Drug Administration’s COSTART system. 27
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Statistical Analysis
All patients who received at least one dose of study medication
were included in the analysis. For base-line comparisons between
the treatment groups, we used Fisher’s exact test for sex, numbers
of adults and children, and race and analysis of variance for age
and body weight. The seizure-frequency data failed to support
the assumption of normality required for a t-test. Therefore, we
used a stratified Wilcoxon rank-sum test 28 to analyze both continuous data (seizure frequency) and categorical data (global assessment of treatment outcome), incorporating “child” and
“adult” as the stratifying variables. The latter statistical analyses
(investigation of data for normality, t-test, and rank-based methods) were specified by the protocol before the study began.
A Spearman rank-correlation test 29 was used to determine the
relation between seizure frequency and the global assessment of
treatment outcome, and the Wilcoxon rank-sum test 30 was used
for both primary efficacy variables for a post hoc analysis of treatment differences for children and for adults.
The statistical tests for the two primary efficacy variables were
two-sided at the 0.025 level of significance, with a Bonferroni
correction31 for testing two outcomes. The significance level was
0.0246, with an adjustment by O’Brien–Fleming procedures32 to
incorporate a penalty for the interim analysis performed at the
0.001 level of significance. The time to a first seizure recurrence
after initial treatment was displayed as Kaplan–Meier survival estimates.33
Fisher’s exact test and the Wilcoxon rank-sum test 30 with exact
P values were computed with StatXact software (version 3, Cytel
Software, Cambridge, Mass.), and analyses of variance by JMP
software (version 3.1, SAS Institute, Cary, N.C.).

RESULTS
Characteristics of the Patients

One hundred twenty-five patients (64 in the diazepam group and 61 in the placebo group) were enrolled and randomly assigned to treatment. This number was less than the 144 patients originally planned,
since the eligibility criteria were very stringent and
funding considerations limited the period of recruitment. Ninety-one of these patients were treated. The
median times from randomization to treatment were
20 days for the diazepam group and 19 days for the
placebo group (exact P=0.95 by the Wilcoxon ranksum test). The diazepam and placebo groups did not
differ significantly in sex, age, and weight (Table 1).
Significantly more black patients were randomly assigned to receive diazepam than were assigned to receive placebo, and significantly more white patients
were assigned to placebo than to diazepam (P=0.04
by Fisher’s exact test). Data from all 91 treated patients were analyzed. A child in the placebo group
who required medical intervention for seizures during treatment was assigned the most conservative
scores (zero seizures, better global assessment).
At the end of the trial, 15 patients who had been
randomly assigned to treatment had not yet had an
episode of acute repetitive seizures: 8 in the diazepam group and 7 in the placebo group. Nineteen
patients had been withdrawn before receiving treatment: 11 in the diazepam group and 8 in the placebo group. Of the 19, 12 became ineligible (6 because of withdrawn consent, 4 because of lack of a

TABLE 1. BASE-LINE CHARACTERISTICS

OF THE

ALL RANDOMIZED PATIENTS
(N=125)

CHARACTERISTIC

Sex (no.)
Male
Female
Race (no.)
White
Black
Other
Age group (no.)
Child
Adult
Median age (yr)
Child
Adult
Median body weight (kg)
Child
Adult

STUDY PATIENTS.
TREATED PATIENTS
(N=91)

DIAZEPAM

PLACEBO

DIAZEPAM

PLACEBO

(N=64)

(N=61)

(N=45)

(N=46)

38
26

32
29

29
16

22
24

44
14
6

53
7
1

29
12
4

40
5
1

36
28

31
30

25
20

22
24

8.0
23.0

8.0
20.5

7.0
18.5

7.0
23.0

23.6
57.1

22.4
60.2

23.0
55.6

21.9
56.8

care giver, 1 because of an added investigational
drug, and 1 because of possible drug allergy); 6 had
no acute repetitive seizures within a year; and 1 was
lost to follow-up. Thus, a total of 34 of the 125
patients received no treatment. Thirteen of the 91
patients who were treated had incomplete dosing
(8 patients), incomplete observations (3 patients),
or both (2 patients).
Study Medication

Forty-one of the 45 treated patients assigned to
diazepam and 40 of the 46 treated patients assigned
to placebo received all their scheduled doses. One of
the 20 adults given diazepam received two doses instead of three, and 3 of the 25 children given diazepam received one dose instead of two. The reasons
included reluctance to give additional doses to a lethargic patient (one patient), rash (one patient), and
the care giver’s noncompliance with the protocol
(two patients). Four of the 24 adults and 2 of the
22 children in the placebo group received fewer doses than planned. In five instances, medical intervention was required for seizures; one care giver misunderstood the treatment directions. Seven patients
(three in the diazepam group and four in the placebo group) received the replacement dose.
The median total dose of diazepam was 20 mg
(range, 7.5 to 25) for the 25 children and 37.5 mg
(range, 15 to 60) for the 20 adults. Most patients received a slightly higher dose than the targeted dose
because of rounding. The median increase over the
target dose was 13.6 percent (range, 4.3 percent decrease to 51.5 percent increase) for the diazepam
group. Six patients, all children, received doses at
least 25 percent greater than the target dose, with
one adverse reaction (moderate somnolence).
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Figure 1. Frequency of Seizures in the Study Groups.
The lower and upper limits of the boxes represent the interquartile range (25th and 75th percentiles, respectively); the heavy
bars represent the median values (for each diazepam group, the
median was zero). The frequency of seizures with diazepam
was significantly lower than that with placebo for all patients
(P<0.001 by stratified Wilcoxon rank-sum test) and, by post hoc
analysis, for children and adults analyzed separately (P<0.001
and P=0.02, respectively, by the Wilcoxon rank-sum test).

Efficacy

Diazepam was significantly more effective than
placebo both for reducing seizure frequency and for
improving the care giver’s global assessment of the
treatment outcome (P<0.001) (Fig. 1 and 2). Seizure frequency and global assessment of treatment
outcome were strongly correlated (Spearman r=0.62,
P<0.001).
For each variable, we compared the treatment responses in children and adults separately. In both
subgroups, the frequency of seizures was significantly
lower in the patients receiving diazepam than in those
receiving placebo (P<0.001 for children and P=0.02
for adults by the Wilcoxon rank-sum test). The care
giver’s global assessment of treatment outcome was
significantly higher for children receiving diazepam
than for children receiving placebo (P<0.001 by the
Wilcoxon rank-sum test), but there was no significant
difference in this outcome variable between the diazepam and placebo groups among adults (P=0.09).
Patients in the diazepam group had greater protection from seizure recurrence throughout the observation period than those in the placebo group.
Differences between the groups were apparent as
early as 30 minutes after initial treatment and con1872 ·

25

Better Same Worse

Better Same Worse

OutcomeH
with Diazepam

OutcomeH
with Placebo

Figure 2. Care Giver’s Global Assessment of Treatment Outcome.
The ratings for global assessment of treatment outcome were
significantly higher for the diazepam group (P<0.001 by the
stratified Wilcoxon rank-sum test for ordinal data).

tinued throughout the 12-hour observation period
(Fig. 3). The time to the first seizure recurrence was
significantly longer in the diazepam group than in
the placebo group (chi-square=13.75 with 1 df,
P<0.001 by the modified Wilcoxon test).
Safety

Fifty-six patients reported no adverse effects of
treatment. There were no reports of respiratory difficulty in patients receiving diazepam. One patient in
the placebo group reported cyanosis. Thirty-five patients reported at least one adverse effect, but the
difference between the diazepam and placebo groups
was not significant: 46.7 percent of the diazepam
group and 30.4 percent of the placebo group (P=
0.13 by Fisher’s exact test). Table 2 lists the adverse
effects reported by more than one patient.
The most frequent adverse effects involved the
nervous system, with at least one such adverse effect
in 40 percent of the diazepam group and 22 percent
of the placebo group. Somnolence, seen in 33 percent of the diazepam group and 11 percent of the
placebo group, was the most frequent. Six patients
receiving placebo required anticonvulsant treatment
at a medical facility for continuing seizures.
Two patients receiving diazepam and two receiving placebo did not complete treatment because of
adverse effects. The third dose was withheld because
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DISCUSSION

We conducted a rigorous, placebo-controlled trial
evaluating the use of diazepam rectal gel in patients
with exacerbations of epileptic seizures. Clinical observations of patients during hospitalization and at
home have suggested that rectal diazepam shortens
the duration of seizures, prevents recurrence, or
both.6,8,16,20-25,34-41 The importance of these studies is
difficult to gauge, however. They were retrospective,
unblinded, or nonrandomized, and they did not use
placebo controls or rigorously define treatment end
points.42 A study similar to ours was conducted by
Milligan et al.,12 who gave 20-mg diazepam suppositories to adults with seizure clusters in a residential
epilepsy center. The investigators used a doubleblind, placebo-controlled design, with each subject
as his or her own control. The nursing staff administered the medications and observed the patients
for 24 hours. Seventy-eight percent of the patients
given diazepam remained seizure-free, as compared
with 19 percent of the patients given placebo. The
analysis was not conducted on intention-to-treat
principles, however, since it excluded data from patients from whom blood specimens were not obtained. Also, results from institutionalized adults
treated by nurses are difficult to extrapolate to patients treated at home, many of whom are children.
We found that diazepam rectal gel was effective
and safe when given outside the hospital for the
treatment of acute repetitive seizures. The superiority of diazepam over placebo was found for both
measures of efficacy: reduction in seizure frequency
and the care giver’s global assessment of treatment
outcome (combining seizure frequency, seizure severity, and drug toxicity). Also, the time to a recurrence of seizures after the initial treatment and the
proportion of patients remaining seizure-free during
the observation period were greater in the diazepam
group. When the efficacy variables were analyzed
separately for children and adults, the reduction in
seizure frequency was significantly greater with diazepam in both age groups, but the care giver’s global
assessment of treatment outcome was significantly
better with diazepam only among children. The difference in outcome between children and adults may
be related to the study design. Three doses were given to adults but only two to children, regardless of
treatment response, and the extra dose of diazepam
may have made the adults more sedated. Also, the
care givers may have watched the children more

100
90
80

Percentage Seizure-free

of marked lethargy in an adult given diazepam, and
the second dose was withheld because of rash in a
child given diazepam. The second and third doses
were withheld because of sedation in an adult given
placebo. The second dose was withheld because of
seizures requiring intravenous diazepam in a child
given placebo.

70

Diazepam

60
50
40
30

Placebo

20
10

P<0.001

0
0

2

4

6

8

10

12

28H
11

28H
11

Hours since First Dose
NO. OF PATIENTS
DiazepamH 45H
Placebo
46

33H
19

30H
14

30H
11

29H
11

Figure 3. Kaplan–Meier Estimate of the Time to a First Recurrence of Seizures.
Data from all patients were censored at 12 hours, the observation period for children. Only two patients, both in the placebo
group, had their first seizure recurrence between 12 and 24
hours after the initial treatment. The vertical bars show 95 percent confidence intervals.

TABLE 2. ADVERSE EFFECTS REPORTED
BY MORE THAN ONE PATIENT.
DIAZEPAM
GROUP

ADVERSE EFFECT*

PLACEBO
GROUP

no. of patients

General
Fever
Headache
Cardiovascular system
Vasodilatation
Digestive system
Anorexia
Vomiting
Nervous system
Abnormal coordination
Dizziness
Euphoria
Nervousness
Somnolence
Respiratory system
Rhinitis
Skin
Pruritus

2
1

2
2

2

0

1
1

2
2

3
2
3
1
15

0
1
0
2
5

0

2

2

0

*The adverse-effect descriptors are from COSTART.27
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closely, resulting in better recognition of differences
in global outcome.
The majority of patients had no adverse effects.
The patients given diazepam had more adverse effects involving the nervous system but fewer digestive and systemic adverse effects than the patients
given placebo. There were no respiratory difficulties.
The benefits of a safe and effective treatment for
acute repetitive seizures were highlighted by Alldredge et al.,43 who reviewed 45 episodes of convulsive status epilepticus in 38 children given prehospital treatment with rectal or intravenous diazepam.
Treatment shortened the duration of status epilepticus by one half and reduced the likelihood that seizures would recur in the emergency department by
one third. In our study, no patients given diazepam
and 13 percent of the patients in the placebo group
required emergency medical care. Kriel et al.23 computed the cost savings associated with in-home rectal diazepam treatment of cluster and prolonged
seizures. They found a 67 percent decrease in emergency room visits and a cost savings of $1,000 per
family in the year after the families begin using rectal
diazepam, with reduced family disruption and improved quality of life.
We also showed that informed and educated care
givers can identify the onset of acute repetitive seizures, safely and successfully administer diazepam
rectally, and assess the patient’s response. The number of doses was fixed to standardize conditions for
this trial. Administration of the second dose in children and adults and of the third dose in adults was
not based on response. In practice, the number and
timing of doses might better be based on the individual patient’s seizure profile and initial response to
treatment.
We did not assess rectal diazepam gel in patients
with acute repetitive seizures who typically progress
to status epilepticus; such patients were ineligible.
Although one patient in the placebo group was apparently in status epilepticus when given the first
dose, no patient in either study group had status epilepticus after treatment was begun.
Supported by contracts with the National Institute of Neurological Disorders and Stroke and Athena Neurosciences.
Dr. Dreifuss, Dr. Cloyd, and Dr. Pellock have served as consultants to
Athena Neurosciences and Upsher–Smith Laboratories, which market and
developed, respectively, rectal diazepam gel.
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